$CURLF

Aurora Cannabis (ACB) disputed inaccuracies in Curaleaf's (CURLF) takeover bid, stating its financial performance is stronger than portrayed. Aurora's board is reviewing the proposal. Curaleaf offered $4.00 per Aurora share, including shares and cash. Aurora's CEO claims the bid undervalues the company and its EU-GMP infrastructure. ACB shares are down 9% YTD, while CURLF shares are up 27%.

Curaleaf's $4 per share hostile bid for Aurora Cannabis led to public disputes. Aurora urged shareholders to wait, calling Curaleaf's claims inaccurate. Curaleaf emphasized its premium offer. Aurora highlighted its EU-GMP facilities and recent acquisitions, while Curaleaf's shares rose 8% in the past year, Aurora's fell 23%.

An informal poll by The Marijuana Herald found 90% of Aurora Cannabis investors oppose Curaleaf's takeover bid, while 64% of Curaleaf investors support it. Aurora investors cite undervaluation, Curaleaf highlights strategic benefits. Curaleaf's offer is $4 per Aurora share, a 45% premium according to the company. Aurora's board is reviewing the offer.

Curaleaf claims Aurora's cultivation yield is 114 grams per plant, per Aurora's audited 2026 statements, and asserts its own yields are more than double. Curaleaf criticizes Aurora's financial performance, citing revenue declines and negative cash flow. Aurora disputes Curaleaf's claims. Curaleaf's offer is based on Aurora's August 5 numbers, with no recommendation from Aurora's Special Committee.

Curaleaf reaffirmed its offer for Aurora, citing a shareholder premium and operational gaps. Curaleaf claims Aurora refused discussions and highlights Aurora's financial struggles, including a 35% YTD share decline and C$4.4M negative operating cash flow. Curaleaf's shares rose 56% over the same period, and it disputes Aurora's financial metrics, citing higher cultivation yields.

Curaleaf Holdings (CURLF) launched a hostile takeover bid for Aurora Cannabis (ACB), offering $4 per share, a 45% premium. Aurora's stock trades below the offer price, indicating skepticism. Curaleaf aims to expand into Canada's medical cannabis market, but regulatory hurdles and profitability concerns remain.

Curaleaf (TSX: CURA, OTCQX: CURLF) responded to Aurora Cannabis' (TSX: ACB, NASDAQ: ACB) statements regarding its takeover offer, citing Aurora's underperformance and lost shareholder value. Curaleaf claims its offer provides a substantial premium and better prospects, while Aurora's management has not engaged constructively. Aurora's share price rose after the offer, trading near the implied value. Curaleaf urges Aurora shareholders to review the offer documents.

Curaleaf Holdings has responded to Aurora Cannabis' rejection of its hostile takeover bid, accusing Aurora of misleading statistics and lost shareholder value. Curaleaf's offer, valued at approximately $4 per share, was deemed undervalued by Aurora, which cited its international medical marijuana business and recent financial progress. Both companies dispute each other's claims regarding financial performance and cultivation productivity.

Curaleaf (CURLF, CURA) defended its US$4.00-per-share offer for Aurora Cannabis (ACB), citing a 35% ACB share-price decline vs. a 56% Curaleaf gain over a year. Curaleaf disputes Aurora's claims, highlighting Aurora's lower cultivation yields, negative cash flow, and weaker fiscal 2027 guidance. Aurora's share price rose after the offer, trading near the implied value, according to Curaleaf.

Aurora Cannabis (ACB) rejected Curaleaf's (CURLF) hostile takeover bid, calling it misleading and urging shareholders to wait. Aurora claims the $4.00 per share offer undervalues the company, citing recent growth and strategic expansions. Curaleaf argues the merger would create an industry leader. Aurora reported 17% international revenue growth and 3 years of positive adjusted EBITDA.